MedTrace Logo

Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma

NCT00003719 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-01-06

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have stage IV or recurrent soft tissue sarcoma that has been previously treated with chemotherapy.

Conditions

  • Sarcoma

Interventions

DRUG

irinotecan hydrochloride

Sponsors & Collaborators

  • Herbert Irving Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Robert N. Taub, MD, PhD · Herbert Irving Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003719 on ClinicalTrials.gov